

Special Issue on
Targeted Molecular Therapy in Glioblastoma

CALL FOR PAPERS

Glioblastoma (GBM) is the most common and malignant type of primary brain tumor. Tumor heterogeneity is a major factor in glioblastoma's poor response to therapy and seemingly inevitable recurrence. The current standard of care for treating newly diagnosed GBMs is maximal safe resection followed by radiation with concurrent and adjuvant temozolomide (Stupp et al., 2005), a regimen which has been shown to improve the median overall survival (12.1 months versus 14.6 months) (Stupp et al., 2005) and the 2-year (27.2% vs. 10.9%) and 5-year (10.9% vs. 1.9%) survival rates compared to radiation alone (Johnson and O'Neill, 2012). There are only four chemotherapeutic agents approved by the Food and Drug Administration (FDA) for treating GBM (lomustine, carmustine, temozolomide, and bevacizumab). Otherwise, multiple randomized phase III clinical trials testing various agents have unfortunately failed to show an improvement in the overall survival of patients with newly diagnosed or recurrent GBM (Seystahl et al., 2016).

This special issue aims to provide a platform for all pharmaceutical and translational scientists and welcomes the submission of original research articles, review articles, and clinical studies focusing on the evaluation of new molecular pathways as pharmacological targets for treatment strategies which may improve the management of aggressive and resistant GBMs.

Potential topics include but are not limited to the following:

- ▶ Mechanisms of resistance to current pharmacological approaches and strategies to overcome the reduced sensitivity
- ▶ Discovery and validation of novel molecular targeted agents
- ▶ Glioma stem-like cells as target for new therapeutic approaches
- ▶ Radio-sensitizing agents
- ▶ Metabolic reprogramming in rapidly growing tumors
- ▶ Immunomodulators and novel immune therapies

Authors can submit their manuscripts through the Manuscript Tracking System at <https://mts.hindawi.com/submit/journals/jo/amtg/>.

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

Claudio Festuccia, Università degli Studi dell'Aquila, L'Aquila, Italy
claudio.festuccia@univaq.it

Guest Editors

Assunta L. Biordi, Università degli Studi dell'Aquila, L'Aquila, Italy
biordi@univaq.it

Vincenzo Tombolini, Sapienza University of Rome, Rome, Italy
vincenzo.tombolini@uniroma1.it

Akira Hara, Gifu University, Gifu, Japan
ahara@gifu-u.ac.jp

David S. Bailey, Cambridge University Biomedical Innovation Hub, Cambridge, UK
david.bailey@iotapharma.com

Submission Deadline

Friday, 15 March 2019

Publication Date

August 2019